List of Onmel drug patents

Onmel is owned by Sebela Ireland Ltd.

Onmel contains Itraconazole.

Onmel has a total of 1 drug patent out of which 0 drug patents have expired.

Onmel was authorised for market use on 29 April, 2010.

Onmel is available in tablet;oral dosage forms.

Onmel can be used as onychomycosis of the toenail caused by tricophyton rubrum or trichophyton mentagrophytes, once daily use for 12 consecutive weeks.

The generics of Onmel are possible to be released after 03 October, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8486456 SEBELA IRELAND LTD Itraconazole compositions with improved bioavailability
Oct, 2028

(5 years from now)

Drugs and Companies using ITRACONAZOLE ingredient

Market Authorisation Date: 29 April, 2010

Treatment: Onychomycosis of the toenail caused by tricophyton rubrum or trichophyton mentagrophytes, once daily use for 12 consecutive weeks

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in